Randomized phase 0/I trial of the mitochondrial inhibitor Me-344 or placebo added to bevacizumab in early HER2-negative breast cancer

1. Quintela-Fandino, M.
2. Morales, S.
3. Cortes-Salgado, A.
4. Manso, L.
5. Apala, J.V.
6. Muñoz, M.
7. Cudos, A.G.
8. Fortuny, J.S.
9. Gion, M.
10. Lopez-Alonso, A.
11. Cortes, J.
12. Guerra, J.
13. Malon, D.
14. Caleiras, E.
15. Mulero, F.
16. Mouron, S.